Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance.
Niklas KlümperDamian J RalserJoerg EllingerFlorian RoghmannJulia AlbrechtEduard BelowAbdullah AlajatiDanijel SikicJohannes BreyerChristian BolenzFriedemann ZengerlingPhilipp ErbenKristina SchwambornRalph M WirtzThomas HornDora NagyMarieta Ioana TomaGlen KristiansenThomas BüttnerOliver HahnViktor GruenwaldChristopher DarrEva ErneSteffen RauschJens BedkeKatrin SchlackMahmoud AbbasStefanie ZschäbitzConstantin SchwabAlexander MusteaPatrick AdamAndreas ManseckBernd WullichManuel RitterArndt HartmannJuergen E GschwendWilko WeichertFranziska ErlmeierMichael HudecekMarkus EcksteinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/ progressive lesion) before initiation of EV.